FDA requirements for reprocessing in pharmaceutical manufacturing center on written procedures and quality control unit oversight. Under 21 CFR 211.115, manufacturers must establish and follow a system for reprocessing nonconforming batches, and obtain quality control unit review and approval before reprocessing.
Reprocessing is a controlled disposition option. It does not replace investigation of the original failure, demonstrate that a batch is suitable for release, or eliminate the need for a scientifically justified decision.
What is pharmaceutical reprocessing?
Reprocessing involves further processing of a batch that does not meet established standards or specifications, with the aim of bringing it into conformance. The proposed approach must be assessed for the specific product and process. Repeating a step can introduce additional risks, including degradation, contamination, altered physical characteristics, or inconsistent performance.
Distinguish reprocessing, rework, routine processing, and retesting in approved procedures. Terminology and regulatory considerations can differ between active ingredients and finished drug products. Do not apply an API-specific concept to a finished product without assessing the relevant framework.
What does 21 CFR 211.115 require?
The regulation requires written procedures describing the reprocessing system and how the resulting batches will meet established standards, specifications, and characteristics. It also makes prior quality control unit review and approval a requirement. This is separate from the later batch-disposition decision.
Investigate the nonconformance before deciding
Start by establishing what failed, which materials or batches may be affected, and what evidence is reliable. Review manufacturing records, laboratory findings, equipment status, hold times, environmental conditions, and relevant changes. Keep the original failure visible in the record.
For an out-of-specification result, follow the applicable investigation process. A passing retest or a favorable post-reprocessing result does not, by itself, explain the original failure or justify excluding it.
A practical reprocessing decision checklist
| Decision | Evidence to document |
|---|---|
| Is the proposal scientifically justified? | Failure mechanism, product knowledge, and rationale for the selected processing steps. |
| Could additional processing affect quality? | Assessment of impurities, stability, microbiological risk, physical attributes, and performance as applicable. |
| Is the proposed approach authorized? | Approved procedure or protocol, quality control unit approval, and regulatory assessment. |
| How will success be evaluated? | Defined tests, acceptance criteria, sampling, and review responsibilities before execution. |
| What supports final disposition? | Executed records, investigation outcome, test results, deviations, and quality review. |
Build a clear written procedure or protocol
State the affected batch identifiers, the process steps, equipment, operating conditions, permitted limits, and required records. Define who may stop the activity and how unexpected findings will be handled. Include any additional sampling or stability commitments supported by the risk assessment.
Keep the distinction between the approved general procedure and the batch-specific rationale clear. A general procedure should not be treated as automatic permission to reprocess every type of failure.
Quality control unit review and batch disposition
Route the investigation and proposed plan for quality review before execution. Assess whether the change could affect registered information, validation status, or other product commitments. Involve regulatory affairs when those questions arise.
After execution, reconcile the actual work with the approved plan. Review deviations, additional results, unresolved uncertainties, and follow-up actions before a release or rejection decision. Document the rationale so another qualified reviewer can reconstruct it.
Common reprocessing mistakes
- Treating waste reduction as the main justification for the decision.
- Starting work before quality control unit approval.
- Using repeat testing to avoid investigating an original failure.
- Changing steps without considering stability or product performance.
- Closing the event without addressing recurrence and corrective action.
Strengthen reprocessing controls
Review a recent event against the checklist above. Confirm that the original failure, proposed intervention, approval, execution, and final disposition form a traceable record. BioBoston Consulting can support cGMP gap assessment and remediation and quality management system improvements.
Common questions about pharmaceutical reprocessing
Can reprocessing begin before quality control unit approval?
No. 21 CFR 211.115(b) requires quality control unit review and approval before reprocessing. A later batch-release review does not substitute for this prior authorization. Keep the approved plan and the subsequent disposition decision separately traceable.
Does a passing result after reprocessing justify releasing the batch?
A passing result alone is insufficient. Review the original failure, investigation, approved reprocessing instructions, execution records, applicable specifications, and potential impact on stability and other quality attributes. The quality control unit must have an adequately supported disposition decision.
Is reprocessing the same as retesting an out-of-specification sample?
No. Reprocessing changes or repeats processing of material; retesting generates additional analytical results. Neither should be used to avoid investigating the original discrepancy. FDA’s OOS investigation guidance explains the assessment of failing test results and the scientific basis needed for further testing.
Sources and regulatory references
- 21 CFR 211.115 — Reprocessing
- 21 CFR 211.192 — Production record review
- FDA guidance: Investigating Out-of-Specification Test Results for Pharmaceutical Production
References checked November 5, 2026. Regulations set binding obligations; agency guidance provides recommendations. Apply the sources within their stated scope and the requirements relevant to your product, activity, and jurisdiction.
